Physician profile
Sandeep Bansal
NPI 1215105267
$1,426,282.44
in general payments reported to CMS, 2019-2025
68 companies · $281K in 2025
The $281K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $88K · 2021: $177K · 2022: $266K · 2023: $275K · 2024: $245K · 2025: $281K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $598K · Travel and Lodging: $106K · Consulting Fee: $51K · Honoraria: $25K · Food and Beverage: $20K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,200 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $598,262.86 |
| Travel and Lodging | $105,523.90 |
| Consulting Fee | $50,866.75 |
| Honoraria | $24,600.00 |
| Food and Beverage | $19,932.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,200.00 |
| Education | $203.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $443,239.46 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $269,438.58 | 2019-2025 | Dupixent |
| Genzyme Corporation | $265,528.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $102,558.37 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78,089.27 | 2019-2025 | Ofev, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $44,952.85 | 2021-2025 | Glassia |
| Ethicon INC. | $44,763.61 | 2019-2023 | Monarch Platform, Monarch |
| Verona Pharma, INC. | $43,052.41 | 2025 | Ohtuvayre |
| Veran Medical Technologies, INC. | $28,535.21 | 2019-2020 | |
| Mylan Specialty L.P. | $18,349.37 | 2022-2024 | Yupelri, Yupelri |
| Noah Medical Corporation | $14,450.81 | 2023-2025 | Galaxy |
| Amgen INC. | $13,824.62 | 2023-2025 | Tezspire |
| Abbott Laboratories | $10,656.51 | 2021-2025 | Aveir |
| Viatris Specialty LLC | $8,327.89 | 2025 | Yupelri |
| Ethicon Endo-Surgery INC. | $7,352.63 | 2022-2023 | Monarch Platform, Monarch |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $7,318.92 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $4,592.50 | 2024 | Dupixent |
| Medical Device Business Services, INC. | $4,400.00 | 2023 | Monarch, Monarch Platform |
| Viiv Healthcare Company | $3,649.06 | 2019 | |
| Chiesi USA, INC. | $2,152.52 | 2023 | |
| Genentech USA, INC. | $1,894.56 | 2021-2023 | Xolair |
| Inspire Medical Systems, INC. | $1,828.69 | 2021-2022 | |
| United Therapeutics Corporation | $1,448.07 | 2021-2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $966.32 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Pulmonx Corporation | $747.96 | 2019-2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Novartis Pharmaceuticals Corporation | $529.30 | 2019-2024 | |
| Philips North America LLC | $436.66 | 2020-2024 | (Ak6) Vest Therapy |
| Galvanize Therapeutics, INC | $400.00 | 2024 | Aliya System |
| Intuitive Surgical, INC. | $381.29 | 2024 | |
| Biosense Webster, INC. | $280.72 | 2024-2025 | Qdot Micro Catheter, Carto 3 |
| Electromed, INC. | $203.71 | 2021-2025 | Smartvest |
| Insmed, INC. | $191.95 | 2019-2025 | Arikayce, Brinsupri |
| Baxter Healthcare | $174.54 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Novo Nordisk INC | $164.06 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $163.30 | 2023-2025 | Zepbound, Mounjaro |
| Rocket Medical LLC | $136.03 | 2022 | |
| Merit Medical Systems INC | $120.40 | 2019 | |
| Merck Sharp & Dohme LLC | $103.51 | 2023-2025 | Winrevair, Keytruda |
| Pfizer INC. | $97.36 | 2023-2025 | |
| Grifols USA, LLC | $88.85 | 2022-2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $79.55 | 2025 | Zemaira |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.73 | 2024-2025 | Lifevest |
| Ambu INC. | $65.89 | 2025 | |
| Medtronic, INC. | $57.11 | 2021 | |
| Paratek Pharmaceuticals, INC. | $49.44 | 2019-2022 | |
| Mauna Kea Technologies, INC. | $45.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $43.22 | 2019-2022 | |
| Sanofi US Services INC. | $29.25 | 2023-2024 | |
| Nabriva Therapeutics, Plc | $27.84 | 2021 | |
| Olympus Corporation of The Americas | $25.76 | 2019 | |
| Gilead Sciences, INC. | $24.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.33 | 2019 | |
| Shire North American Group INC | $22.84 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $19.69 | 2025 | Lumryz |
| Tactile Systems Technology INC | $17.60 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.51 | 2019 | |
| Apria Healthcare LLC | $16.66 | 2021 | |
| Advanced Respiratory, INC | $16.44 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.70 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.95 | 2022 | |
| Monaghan Medical Corporation | $12.30 | 2021 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,379.64 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.